By classification, the two compounds occupy adjacent but separate categories within GH-axis research. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), structurally derived from the N-terminal fragment of the native GHRH peptide. It is studied as a GHRH-receptor-directed research agent. Ipamorelin, by contrast, is classified as a growth hormone secretagogue (GHS) and a ghrelin/GHS-receptor-directed peptide — a member of the secretagogue class rather than a GHRH analog. The distinction matters for experimental design because the two are associated with different receptor systems in the published research literature, even though both are catalogued under GH-axis peptide studies.
Structurally, the two differ markedly in size and complexity. Ipamorelin is a short synthetic peptide of the pentapeptide class, notable for incorporating non-proteinogenic and D-configured residues that give it a compact, non-natural backbone characteristic of engineered secretagogues. CJC-1295 is a substantially longer chain built on a modified GHRH-analog scaffold; it contains amino-acid substitutions engineered to increase resistance to enzymatic cleavage relative to the parent GHRH fragment. Some catalog variants of CJC-1295 additionally incorporate a Drug Affinity Complex (DAC) moiety, a conjugation intended to increase the construct's resistance to enzymatic clearance in research models, whereas the non-DAC variant (often labeled "modified GRF 1-29") omits that group. Ipamorelin carries no such conjugation and is a purely peptidic, unconjugated small peptide.
In terms of molecular profile, the practical contrast is one of scale: Ipamorelin's low residue count places it firmly among small research peptides, giving a comparatively low molecular weight, while CJC-1295's extended analog backbone (and, in the DAC variant, its appended complex) places it among larger, higher-molecular-weight peptide constructs. Because specific numeric molecular constants were not supplied for this comparison, exact formulas, masses, and identifiers are intentionally omitted here; researchers should confirm these against the Certificate of Analysis (CoA) accompanying a given lot. Both classes are routinely characterized analytically by reversed-phase HPLC for purity and by mass spectrometry for identity confirmation.
Regarding physical format, both peptides are most commonly supplied as a sterile, lyophilized (freeze-dried) white-to-off-white powder sealed in a vial, a form chosen for solid-state stability during shipping and storage. In this state each is typically handled as a research reagent to be reconstituted with an appropriate sterile solvent immediately prior to bench work, following standard peptide reconstitution chemistry; lyophilized material is generally stored cold and protected from moisture and light, with reconstituted solutions kept refrigerated and used within a short window. The formats are therefore closely comparable at the point of receipt, with the principal differences lying in molecular size and solubility behavior rather than in outward presentation.